http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Regeneron (REGN) Genetics Center Publication in NEJM Identifies New Genetic Variant Providing Protection from Chronic Liver Disease
-
Regeneron (REGN) and Alnylam (ALNY) Announce Pact to Discover New Treatments for NASH
-
Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH)
-
Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease
-
Regeneron (REGN) Says EYLEA Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
-
EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
-
Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease
-
Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease
-
Regeneron (REGN) and Sanofi (SNY) Announce Praluent Met Primary Endpoint of Reducing Cardiovascular Events
-
Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
-
Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
-
Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
-
Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need
-
Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
-
Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
-
Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate
-
Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
-
Regeneron (REGN) & Sanofi (SNY) Announce DUPIXENT Accepted for FDA Review
-
Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
-
Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
-
FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
-
Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
-
Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
-
Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018
-
Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018
-
Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018
-
Regeneron (REGN) Reports Approval of DUPIXENT in Japan for Treatment of Atopic Dermatitis
-
Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis
-
Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs
-
Sanofi (SNY), Regeneron (REGN) to accelerate, expand investment for cemiplimab and dupilumab development programs
-
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
-
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
-
Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank
-
Regeneron Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference
-
Regeneron (REGN) Announces Strategic Immuno-Oncology Collaboration with ISA Pharmaceuticals
-
ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration
-
Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration
-
Regeneron (REGN) & Sanofi (SNY) Report Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab
-
Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day
-
Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma
-
Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma
-
Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
-
Regeneron (REGN) Says FDA Accepted sBLA Filing for 12-Week Dosing of EYLEA Injection for Patients with Wet AMD
-
Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD
-
Regeneron (REGN) and Decibel Therapeutics Announce Pact to Discover and Develop Therapeutics for Hearing Loss and Tinnitus
-
Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus
-
Regeneron (REGN) Reports Update on EYLEA (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
-
Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
-
Regeneron Announces Upcoming Investor Conference Presentation
-
Regeneron Reports Third Quarter 2017 Financial and Operating Results
